16 March 2022
SkinBioTherapeutics plc
Notice of Results
SkinBioTherapeutics plc's (AIM: SBTX or the "Company") interim financial results for the six months to 31 December 2021 will be released on Tuesday 29 March 2022.
-Ends-
For more information please contact:
|
SkinBioTherapeutics plc Stuart J. Ashman, CEO Doug Quinn, CFO |
Tel: +44 (0) 161 468 2760 |
|
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Michael Johnson, Dale Bellis (Sales) |
Tel: +44 (0) 20 7397 8900 |
|
Instinctif Partners (financial press) Melanie Toyne-Sewell / Nathan Billis |
Tel: +44 (0) 20 7457 2020 |
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AsixBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
